Streck Unveils Enhanced ARM-D® Kit, OXA with Broader Gene Variants Detection
Streck’s Enhanced ARM-D® Kit: Redefining Antimicrobial Detection
In a groundbreaking development for public health laboratories, Streck has announced the release of an upgraded version of the ARM-D® Kit, OXA. This innovative product is now equipped to detect an additional 36 allelic variants across three novel antimicrobial resistance (AR) gene families, significantly expanding its testing capabilities. This update is a direct response to demands from customers, particularly those within the Antimicrobial Resistance Laboratory Network (ARLN) and the Centers for Disease Control and Prevention (CDC).
The Need for Enhanced Detection
As antimicrobial resistance grows increasingly complex, identifying diverse allelic variants has become more vital than ever. Laboratories have reported a wider range of gene families and allelic variants that necessitate robust surveillance capabilities. A key focus for these labs is the effective detection of variants such as OXA-235, OXA-236, and OXA-237 from the OXA-134 family, in addition to OXA-327-like and OXA-198-like beta-lactamase enzymes.
Chris Connelly, Director of Business Segment – Molecular at Streck, remarked on the significance of this expansion: “The enhancement of the ARM-D Kit, OXA illustrates our unwavering commitment to meet the needs of public health laboratories. We aim to contribute globally to the advancement of infectious disease testing strategies.”
Features of the ARM-D Kit, OXA
Streck’s ARM-D kits facilitate the efficient and comprehensive detection of over 2,000 allelic variants within 25 AR gene families. These kits are acclaimed for their accuracy, demonstrating 100% concordance with whole genome sequencing (WGS) data from identical samples. Such features make them ideal for pre-WGS screening, thus minimizing costs related to AR surveillance in public health settings throughout the U.S. and globally.
As a testament to its reliability, the ARM-D Kit, OXA has been employed in various public health laboratories, where it has proven to be a cost-effective solution while ensuring the accuracy and reliability of AR testing.
A Commitment to Public Health
The introduction of the enhanced ARM-D® Kit reinforces Streck’s dedication to providing tools that empower laboratories to deliver precise results, advancing the field of diagnostics. Established in 1971, Streck has consistently strived to enhance the reliability of clinical and research laboratories, ultimately contributing to healthier lives for patients worldwide.
Manufactured in La Vista, Nebraska, Streck products are distributed across thousands of laboratories globally, ensuring that all results are data-driven and impactful.
Conclusion
With the launch of the enhanced ARM-D® Kit, OXA, Streck is not just updating its product line but is also reinforcing its role as a pivotal player in the global fight against antimicrobial resistance. By addressing the specific needs of its clients in public health, Streck continues to ensure that every result counts. The ARM-D Kit, OXA is strictly for research purposes and is not intended for diagnostic use, emphasizing the importance of continuous innovation and reliability in medical testing.
For any inquiries or further information, please contact Chris Connelly, Director of Business Segment - Molecular, at [email protected]